BACKGROUND: Wild waterfowl is the natural reservoir of influenza A virus (IAV); hosted viruses are very variable and provide a source for genetic segments which can reassort with poultry or mammalian adapted IAVs to generate novel species crossing viruses. Additionally, wild waterfowl act as a reservoir for highly pathogenic IAVs. Exposure of wild birds to the antiviral drug oseltamivir may occur in the environment as its active metabolite can be released from sewage treatment plants to river water. Resistance to oseltamivir, or to other neuraminidase inhibitors (NAIs), in IAVs of wild waterfowl has not been extensively studied. AIM AND METHODS: In a previous in vivo Mallard experiment, an influenza A(H6N2) virus developed oseltamivir resistance by the R292K substitution in the neuraminidase (NA), when the birds were exposed to oseltamivir. In this study we tested if the resistance could be maintained in Mallards without drug exposure. Three variants of resistant H6N2/R292K virus were each propagated during 17 days in five successive pairs of naïve Mallards, while oseltamivir exposure was decreased and removed. Daily fecal samples were analyzed for viral presence, genotype and phenotype. RESULTS AND CONCLUSION: Within three days without drug exposure no resistant viruses could be detected by NA sequencing, which was confirmed by functional NAI sensitivity testing. We conclude that this resistant N2 virus could not compete in fitness with wild type subpopulations without oseltamivir drug pressure, and thus has no potential to circulate among wild birds. The results of this study contrast to previous observations of drug induced resistance in an avian H1N1 virus, which was maintained also without drug exposure in Mallards. Experimental observations on persistence of NAI resistance in avian IAVs resemble NAI resistance seen in human IAVs, in which resistant N2 subtypes do not circulate, while N1 subtypes with permissive mutations can circulate without drug pressure. We speculate that the phylogenetic group N1 NAs may easier compensate for NAI resistance than group N2 NAs, though further studies are needed to confirm such conclusions.

Centre for Ecology and Evolution in Microbial Model Systems Linnaeus University Kalmar Sweden

Department of Biomedical Sciences and Veterinary Public Health Swedish University of Agricultural Sciences Uppsala Sweden

Department of Chemistry Umeå University Umeå Sweden

Department of Chemistry Umeå University Umeå Sweden; Faculty of Fisheries and Protection of Waters South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses Vodnany University of South Bohemia in Ceske Budejovice Ceske Budejovice Czech Republic

Department of Virology Immunobiology and Parasitology Swedish Veterinary Institute Uppsala Sweden

Section for Infectious Diseases Department of Medical Sciences Uppsala University Uppsala Sweden; Zoonosis Science Centre Department of Medical Biochemistry and Microbiology Uppsala University Uppsala Sweden

Zobrazit více v PubMed

Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22–9. 10.1016/j.coviro.2014.04.009 PubMed DOI

World Health Organization. Recommended composition of influenza virus vaccines for use in the 2015–2016 northern hemisphere influenza season. Wkly Epidemiol Rec. 2015;90(11):97–108. PubMed

Rogers MB, Song T, Sebra R, Greenbaum BD, Hamelin ME, Fitch A, et al. Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection. MBio. 2015;6(2). 10.1128/mBio.02464-14 PubMed DOI PMC

Duan S, Govorkova EA, Bahl J, Zaraket H, Baranovich T, Seiler P, et al. Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses. Nat Commun. 2014;5:5029 10.1038/ncomms6029 PubMed DOI PMC

Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98(2):174–85. 10.1016/j.antiviral.2013.03.014 PubMed DOI

Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, et al. Structural basis for oseltamivir resistance of influenza viruses. Vaccine. 2009;27(45):6317–23. 10.1016/j.vaccine.2009.07.017 PubMed DOI

Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006;443(7107):45–9. PubMed

Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD, Fouchier RA. Global patterns of influenza A virus in wild birds. Science. 2006;312(5772):384–8. PubMed

Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992;56(1):152–79. PubMed PMC

Dugan VG, Chen R, Spiro DJ, Sengamalay N, Zaborsky J, Ghedin E, et al. The evolutionary genetics and emergence of avian influenza viruses in wild birds. PLoS Pathog. 2008;4(5):e1000076 10.1371/journal.ppat.1000076 PubMed DOI PMC

Latorre-Margalef N, Grosbois V, Wahlgren J, Munster VJ, Tolf C, Fouchier RAM, et al. Heterosubtypic Immunity to Influenza A Virus Infections in Mallards May Explain Existence of Multiple Virus Subtypes. PLoS Pathogens. 2013;9(6):e1003443 10.1371/journal.ppat.1003443 PubMed DOI PMC

Wang TT, Palese P. Emergence and evolution of the 1918, 1957,1968 and 2009 pandemic virus strains In: Webster RG, Monto AS, Braciale TJ, Lamb RA, eds. Textbook of Influenza. Oxford, UK: John Wiley & Sons, Ltd; 2013:218–28.

Wille M, Tolf C, Avril A, Latorre-Margalef N, Wallerstrom S, Olsen B, et al. Frequency and patterns of reassortment in natural influenza A virus infection in a reservoir host. Virology. 2013;443(1):150–60. 10.1016/j.virol.2013.05.004 PubMed DOI

Forrest HL, Webster RG. Perspectives on influenza evolution and the role of research. Animal Health Research Reviews. 2010;11(1):3–18. 10.1017/S1466252310000071 PubMed DOI

Soderstrom H, Jarhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS One. 2009;4(6):e6064 10.1371/journal.pone.0006064 PubMed DOI PMC

Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S. Detection of antiviral drugs oseltamivir phosphate and oseltamivir carboxylate in Neya River, Osaka Japan. Journal of Water and Environment Technology. 2010;8(4):363–72.

Azuma T, Nakada N, Yamashita N, Tanaka H. Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak. Environ Sci Technol. 2012;46(23):12873–81. 10.1021/es303203c PubMed DOI

Ghosh GC, Nakada N, Yamashita N, Tanaka H. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect. 2010;118(1):103–7. 10.1289/ehp.0900930 PubMed DOI PMC

Prasse C, Schlusener MP, Schulz R, Ternes TA. Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance? Environ Sci Technol. 2010;44(5):1728–35. 10.1021/es903216p PubMed DOI

Goncalves C, Perez S, Osorio V, Petrovic M, Alpendurada MF, Barcelo D. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence. Environ Sci Technol. 2011;45(10):4307–14. 10.1021/es1032629 PubMed DOI

Singer AC, Jarhult JD, Grabic R, Khan GA, Lindberg RH, Fedorova G, et al. Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers. PLoS One. 2014;9(9):e108621 10.1371/journal.pone.0108621 PubMed DOI PMC

Stoner TD, Krauss S, Turner JC, Seiler P, Negovetich NJ, Stallknecht DE, et al. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. Antiviral Res. 2012;93(3):322–9. 10.1016/j.antiviral.2011.12.013 PubMed DOI PMC

Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, et al. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol. 2010;84(19):9800–9. 10.1128/JVI.00296-10 PubMed DOI PMC

Orozovic G, Orozovic K, Järhult JD, Olsen B. Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden. 2014. PubMed PMC

Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Davis CT, Villanueva JM, et al. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses. J Virol. 2015;89(10):5419–26. 10.1128/JVI.03513-14 PubMed DOI PMC

de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353(25):2667–72. PubMed

Earhart KC, Elsayed NM, Saad MD, Gubareva LV, Nayel A, Deyde VM, et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health. 2009;2(2):74–80. 10.1016/j.jiph.2009.04.004 PubMed DOI

Qi W, Zhou X, Shi W, Huang L, Xia W, Liu D, et al. Genesis of the novel human-infecting influenza A(H10N8) virus and potential genetic diversity of the virus in poultry, China. Euro Surveill. 2014;19(25). PubMed

Jarhult JD, Muradrasoli S, Wahlgren J, Soderstrom H, Orozovic G, Gunnarsson G, et al. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. PLoS One. 2011;6(9):e24742 10.1371/journal.pone.0024742 PubMed DOI PMC

Gillman A, Muradrasoli S, Soderstrom H, Holmberg F, Latorre-Margalef N, Tolf C, et al. Oseltamivir-Resistant Influenza A (H1N1) Virus Strain with an H274Y Mutation in Neuraminidase Persists without Drug Pressure in Infected Mallards. Appl Environ Microbiol. 2015;81(7):2378–83. 10.1128/AEM.04034-14 PubMed DOI PMC

Gillman A, Muradrasoli S, Soderstrom H, Nordh J, Brojer C, Lindberg RH, et al. Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir. PLoS One. 2013;8(8):e71230 10.1371/journal.pone.0071230 PubMed DOI PMC

Latorre-Margalef N, Gunnarsson G, Munster VJ, Fouchier RA, Osterhaus AD, Elmberg J, et al. Effects of influenza A virus infection on migrating mallard ducks. Proc Biol Sci. 2009;276(1659):1029–36. 10.1098/rspb.2008.1501 PubMed DOI PMC

Hurt A. Flourometric Neuraminidase Inhibition Assay, Standard Operating Procedure WHO-025, Official copy. WHO collaborating centre for reference & research on influenza, Austalia. 2007.

Spackman E, Suarez DL. Type A influenza virus detection and quantitation by real-time RT-PCR. Methods Mol Biol. 2008;436:19–26. 10.1007/978-1-59745-279-3_4 PubMed DOI

Lackenby A. Determination of influenza virus susceptibility to neuraminidase inhibitors using a fluorescent substrate. Neuraminidase Inhibitor Surveillance Network; 2008. v: 24-05-2008:1–15.

Khan GA, Lindberg R, Grabic R, Fick J. The development and application of a system for simultaneously determining anti-infectives and nasal decongestants using on-line solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012;66:24–32. 10.1016/j.jpba.2012.02.011 PubMed DOI

Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol. 2008;41(1):13–9. PubMed

Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog. 2014;10(4):e1004065 10.1371/journal.ppat.1004065 PubMed DOI PMC